Format

Send to

Choose Destination
Int J Cancer. 2016 Jul 1;139(1):75-84. doi: 10.1002/ijc.30042. Epub 2016 Mar 2.

TERT promoter mutations in melanoma survival.

Author information

1
Department of Dermatology, Instituto Valenciano De Oncologia, Valencia, Spain.
2
Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
3
Laboratory of Molecular Biology, Instituto Valenciano De Oncologia, Valencia, Spain.
4
Medical Oncology Department, Instituto Valenciano De Oncologia, Valencia, Spain.
5
Department of Pathology, Instituto Valenciano De Oncologia, Valencia, Spain.
6
Department of Dermatology, Hospital Arnau De Vilanova De Valencia, Valencia, Spain.
7
Department of Pathology, Hospital Arnau De Vilanova De Valencia, Valencia, Spain.
8
Center for Primary Health Care Research, Lund University, Malmö, Sweden.
9
Division of Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD.

Abstract

Despite advances in targeted therapies, the treatment of advanced melanoma remains an exercise in disease management, hence a need for biomarkers for identification of at-risk primary melanoma patients. In this study, we aimed to assess the prognostic value of TERT promoter mutations in primary melanomas. Tumors from 300 patients with stage I/II melanoma were sequenced for TERT promoter and BRAF/NRAS mutations. Cumulative curves were drawn for patients with and without mutations with progression-free and melanoma-specific survival as outcomes. Cox proportional hazard regression models were used to determine the effect of the mutations on survivals. Individually, presence of TERT promoter and BRAF/NRAS mutations associated with poor disease-free and melanoma-specific survival with modification of the effect by the rs2853669 polymorphism within the TERT promoter. Hazard ratio (HR) for simultaneous occurrence of TERT promoter and BRAF/NRAS mutations for disease-free survival was 2.3 (95% CI 1.2-4.4) and for melanoma-specific survival 5.8 (95% CI 1.9-18.3). The effect of the mutations on melanoma-specific survival in noncarriers of variant allele of the polymorphism was significant (HR 4.5, 95% CI 1.4-15.2) but could not be calculated for the carriers due to low number of events. The variant allele per se showed association with increased survival (HR 0.3, 95% CI 0.1-0.9). The data in this study provide preliminary evidence that TERT promoter mutations in combination with BRAF/NRAS mutations can be used to identify patients at risk of aggressive disease and the possibility of refinement of the classification with inclusion of the rs2853669 polymorphism within TERT promoter.

KEYWORDS:

BRAF mutations; TERT promoter mutations; disease-free survival; melanoma; melanoma-specific survival

PMID:
26875008
DOI:
10.1002/ijc.30042
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center